Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients

Transplantation

Volumn 70, Issue 6, 2000, Pages 887-895

  Montgomery, Robert A ^a   Zachary, Andrea A ^a   Racusen, Lorraine C ^a   Leffell, Mary S ^a   King, Karen E ^a   Burdick, James ^a   Maley, Warren R ^a   Ratner, Lloyd E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CROSS TOLERANCE; FEMALE; GRAFT REJECTION; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PRIORITY JOURNAL;

EID: 0034721477     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200009270-00006     Document Type: Article

References (64)

1. 'Hyperacute' renal-homograft rejection in man
2. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells
3. Significance of the positive crossmatch test in renal transplantation
4. The significance of anti-class I antibody response: Clinical and pathologic features of anti-class I mediated rejection
5. Identification of patients at high risk of graft loss by pre- and posttransplant monitoring of anti-HLA class I IgG antibodies by enzyme-linked immunosorbent assay
6. Characterization of lymphocytotoxity crossmatches causing a positive crossmatch in renal transplantation: Relationship to primary and regraft outcome
7. 5-year follow-up of patients successfully transplanted after immunoadsorption to remove anti-HLA antibodies
8. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation
9. Fewer acute rejection episodes and improved outcome in kidney transplanted patients with selection criteria based on crossmatching
10. Renal transplantation after removal and prevention of resynthesis of HLA antibodies
11. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation
12. Plasma exchange and immunoadsorption prior to renal transplantation in allosensitized patients
13. Pretransplant removal of anti-HLA antibodies by plasmapheresis and continued suppression on cyclosporine-based therapy after heart-kidney transplant
14. Renal transplantation following immunoadsorption in highly sensitized recipients
15. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation
16. Measures to decrease HLA antibodies in immunized patients awaiting kidney transplantation
17. Pretransplantation plasmapheresis in HLA-sensitized patients: Five years experience
18. Anti-HLA antibody removal in hyperimmunizied ESRF patients to allow transplantation
19. Effect of protein A immunoadsorption on panel lymphocyte reactivity in hyperimmunized patients awaiting a kidney graft
20. Disappearance of anti-HLA antibodies in highly sensitized patients treated with erythropoietin
21. Manipulating the immune system with immune globulin
22. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and Factor VIII
23. Treatment of platelet alloimmunization with intravenous immunoglobulin
24. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thromocytopenic patients
25. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ
26. Suppression of HLA-specific alloantibodies by high dose intravenous immunoglobulins (IVIg): A potential tool for transplantation of immunized patients
27. Immunoglobulin G dimer: An idiotype-anti-idiotype complex
28. Antiiodiotypic suppression of autoantibodies with normal polyspecific immunoglobulins
29. Anti-idiotypes against autoantibodies and alloantibodies to VII: C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins
30. Recovery from anti-VIII: C (anti-haemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-VIII: C antibodies
31. The basic lymphocyte microcytotoxity tests
32. Flow cytometry in the transplant laboratory
33. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome
34. The significance of anti-class I like antibody
35. Risk factors for second renal allografts immunosuppressed with cyclosporine
36. Prognostic indices to predict survival of first and second renal allografts
37. Complementary data about the inhibitory effects of intravenous immunoglobulins in vitro and in vivo
38. The relationship between flow cytometer crossmatch results and subsequent rejection episodes in cadaver renal allograft recipients
39. Renal transplantation: The role of race, quadruple immunosuppression, and the flow cytometry crossmatch
40. Donor-specific antibodies after transplantation by flow cytometry
41. Flow crossmatching identifies patients at risk for postoperative elaboration of cytotoxic antibodies
42. Postoperative production of anti-donor antibody and early graft loss due to vascular rejection in renal transplantation
43. An approach to reducing early kidney transplant failure by flow cytometry crossmatching
44. T cell immunofluorescence flow cytometry crossmatch results in cadaver donor renal transplantation
45. Flow cytometry crossmatching in human cadaver kidney transplantation
46. Renal transplantation and B-cell crossmatches with autoantibodies and alloantibodies
47. Presence of IgG HLA antibodies in patients with long-surviving renal allografts
48. Donor specific CDC lymphocyte crossmatch and five year allograft survival
49. Successful renal transplantation in patients with T-cell reactivity to donor
50. Immunoglobulin class and specificity of antibodies causing positive T-cell crossmatches (relationship to renal transplant outcome)
51. Treatment of acute humoral rejection in kidney transplantation with plasmapheresis
52. Removal of lymphocytotoxic antibodies by pretransplant immunoadsorption therapy in highly sensitized renal transplant recipients
53. Beneficial effects of double-filtration plasmapheresis on living related donor renal transplantation in presensitized recipients
54. Posttransplant therapy using high-dose human immunoglobulin (intravenous gamma-globulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action
55. Successful kidney transplantation of immunized patients after desensitization with normal human polyclonal immunoglobulins
56. Intravenous gamma globulin (IVIg) inhibits lymphocytotoxic antibody in vitro
57. Inhibition of anti-HLA antibodies (ab) cytotoxicity and synthesis by intravenous polyclonal immunoglobulins (IVIg)
58. Intravenous immunoglobulin (IVIg) reduces antibody responses in highly sensitized dialysis patients
59. Treatment of autoimmune disease with normal immunoglobulin through manipulation of the idiotypic network
60. Treatment of autoimmune disease and systemic vasculitis with pooled human intravenous immune globulin
61. Pooled human IgG mudulates cytokine production in lymphocytes and monocytes
62. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood monuclear cells by IVIg
63. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor Beta chain
64. Plasma exchange and tacrolimus-myocphenolate rescue for acute humoral rejection in kidney transplantation